Compare Fubotv Inc (FUBO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Organon & Co. Common Stock — how do they compare? Fubotv Inc trades at $8.22 (market cap $894.32M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 4× Fubotv Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Organon & Co. Common Stock for 0 Days on average.
| FUBO | OGN | |
|---|---|---|
Market Cap | $894.32M | $3.62B |
Volume | 1,279,134 | 2,892,999 |
Sector | Media | Health |
52-Week High | $48.96 | $13.81 |
52-Week Low | $8.09 | $5.70 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $1.07B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $8.26, down 5.49% on the day, reflecting a bearish technical trend. The stock shows deep undervaluation with a P/E of 2.13 and P/S of 0.16, but fundamentals are mixed with a net loss of $172.25M in 2024 despite revenue growth to $1.62B. Recent news highlights strategic partnerships, including NHL streaming deals and the launch of My Local Sports, aiming to boost subscriber growth and advertising revenue.
The outlook remains speculative; a projected net profit of $123M in 2025 suggests a potential turnaround, but persistent cash burn and high debt levels pose significant risks. Analyst consensus is divided with a $63.38 price target, indicating substantial upside if execution improves, yet the bearish technical signals and competitive pressures warrant caution for investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
